Yes it was deemed statistically significant so NEU have definitely ticked the p2 box... but if I am Pfizer sitting at the table with 2 potential deals infront of me with the same potential impact to my revenue, one of them is positive based on chaging blood readings and the other is positive based on opinions, which is the less risky? Or is there that much pent up demand in large pharma as some here think that I take both? I'm not sure.
Add to My Watchlist
What is My Watchlist?
